Folgen
Thomas P. Peacock
Thomas P. Peacock
Fellow, The Pirbright Instititute; Lecturer (Honorary), Imperial College London
Bestätigte E-Mail-Adresse bei ic.ac.uk
Titel
Zitiert von
Zitiert von
Jahr
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
P Mlcochova, SA Kemp, MS Dhar, G Papa, B Meng, IATM Ferreira, R Datir, ...
Nature 599 (7883), 114-119, 2021
1596*2021
SARS-CoV-2 variant biology: immune escape, transmission and fitness
AM Carabelli, TP Peacock, LG Thorne, WT Harvey, J Hughes, ...
Nature Reviews Microbiology 21 (3), 162-177, 2023
10442023
Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations
A Rambaut, N Loman, O Pybus, W Barclay, J Barrett, A Carabelli, ...
virological.org, 1-5, 2020
975*2020
The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets
TP Peacock, DH Goldhill, J Zhou, L Baillon, R Frise, OC Swann, ...
Nature Microbiology 6 (7), 899-909, 2021
811*2021
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa
H Tegally, M Moir, J Everatt, M Giovanetti, C Scheepers, E Wilkinson, ...
Nature medicine, 1-1, 2022
735*2022
The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein
TP Peacock, JC Brown, J Zhou, N Thakur, K Sukhova, J Newman, ...
bioRxiv, 2022
398*2022
A global perspective on H9N2 avian influenza virus.
TP Peacock, J James, JE Sealy, M Iqbal
Viruses 11 (620), 2019
348*2019
SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
MG Cox, TP Peacock, WT Harvey, J Hughes, DW Wright, ...
Nature Reviews Microbiology 21 (2), 112-124, 2023
2602023
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
C Davis, N Logan, G Tyson, R Orton, WT Harvey, JS Perkins, G Mollett, ...
PLoS Pathogens 17 (12), e1010022, 2021
223*2021
Affimer proteins are versatile and renewable affinity reagents
C Tiede, R Bedford, SJ Heseltine, G Smith, I Wijetunga, R Ross, ...
Elife 6, e24903, 2017
2222017
SARS-CoV-2 one year on: evidence for ongoing viral adaptation
TP Peacock, R Penrice-Randal, JA Hiscox, WS Barclay
Journal of General Virology 102 (4), 001584, 2021
1682021
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
T Sanderson, R Hisner, I Donovan-Banfield, H Hartman, A Løchen, ...
Nature 623 (7987), 594-600, 2023
1282023
The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK
V Hill, L Du Plessis, TP Peacock, D Aggarwal, R Colquhoun, AM Carabelli, ...
Virus Evolution 8 (2), veac080, 2022
1202022
KAP1 regulates endogenous retroviruses in adult human cells and contributes to innate immune control
CHC Tie, L Fernandes, L Conde, L Robbez‐Masson, RP Sumner, ...
EMBO reports 19 (10), e45000, 2018
1142018
The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin
TP Peacock, CM Sheppard, JC Brown, N Goonawardane, J Zhou, ...
bioRxiv, 2021
109*2021
Context-specific emergence and growth of the SARS-CoV-2 Delta variant
JT McCrone, V Hill, S Bajaj, RE Pena, BC Lambert, R Inward, S Bhatt, ...
Nature 610 (7930), 154-160, 2022
1072022
Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape
JC Brown, DH Goldhill, J Zhou, TP Peacock, R Frise, N Goonawardane, ...
bioRxiv, 2021
101*2021
Recurrent SARS-CoV-2 mutations in immunodeficient patients
SAJ Wilkinson, A Richter, A Casey, H Osman, JD Mirza, J Stockton, ...
Virus evolution 8 (2), veac050, 2022
882022
Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
DJ Sheward, C Kim, J Fischbach, K Sato, S Muschiol, RA Ehling, ...
The Lancet Infectious Diseases 22 (11), 1538-1540, 2022
862022
Evasion of neutralising antibodies by omicron sublineage BA.2.75
DJ Sheward, C Kim, J Fischbach, S Muschiol, RA Ehling, NK Björkström, ...
The Lancet Infectious Diseases, 2022
862022
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20